Related Experiment Video
Updated: Jun 21, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
[A community acquired pneumonia case caused by Ralstonia pickettii]
Abdulkadir Küçükbayrak1, Feza Uğurman, Necla Dereli
1Atatürk GögüUs Hastaliklanr ve Cögus Cerrahisi Egitim ve Araştirma Hastanesi, Enfeksiyon Hastaliklan ve Klinik Mikrobiyoloji Kliniği, Ankara. abdulbayrak@yahoo.com
Abstract:
Ralstonia pickettii, formerly known as Burkholderia pickettii, is a non-fermentative gram-negative bacillus. It is emerging as an opportunistic pathogen both in the hospital setting and in the environment, leading to outbreaks especially in the intensive care units. The available literature revealed two case reports of pneumonia associated with R. pickettii in adults. In this report, a case of pneumoniae due to R. pickettii, in a patient with chronic obstructive pulmonary disease was presented. Fifty-six years old male patient was admitted to the hospital with complaints of shortness of breath, cough, purulent sputum, weakness, fatigue and green colorred diarrhea lacking blood. Lung auscultation revealed decreased respiratory sounds in the right lower lobe. Laboratory findings yielded decreased arterial pH and paO2 and increased pCO2 values, while hemoglobin, hematocrite, blood urea and creatinine levels were increased. Chest X-ray showed an infiltration on right lower zone. The patient was intubated and imipenem 1 x 500 mg/day and netilmicin 1 x 80 mg/day were initiated. Deep tracheal aspirate specimen revealed gram-negative rods and leukocytes, and cultures yielded growth of non-fermentative gram-negative bacilli on blood agar and EMB agar. These bacilli were identified as R. pickettii by using VITEK 2 system (bi-oMerieux Inc, Mercy L'etoil, France). Antibiotic sensitivity test performed by VITEK 2 GP system (bioMerieux Inc, Mercy L'etoil, France) revealed sensitivity to ceftriaxone, imipenem/cilastatin, piperacillin/tazobactam, amikacin, gentamicin, cefoperazone-sulbactam and ciprofloxacin. Treatment with imipenem/cilastatin was continued for 14 days and the patient was completely recovered. This case was presented in order to call attention to R. pickettii as a pathogen that may cause community-acquired lower respiratory tract infection.
Insights
Ralstonia pickettii, an opportunistic pathogen, caused community-acquired pneumonia in a patient with COPD. Prompt antibiotic treatment led to full recovery, highlighting its potential as a respiratory tract pathogen.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Pulmonology
Background:
- Ralstonia pickettii (formerly Burkholderia pickettii) is an opportunistic Gram-negative bacillus increasingly implicated in hospital and environmental outbreaks.
- Literature review indicates limited reports of pneumonia caused by R. pickettii in adults, with a specific need to understand its role in community-acquired infections.
Observation:
- A 56-year-old male with chronic obstructive pulmonary disease (COPD) presented with severe respiratory distress, cough, purulent sputum, and diarrhea.
- Clinical examination revealed decreased breath sounds, and laboratory tests showed impaired gas exchange (low pH, paO2; high pCO2) and elevated markers of infection and renal function.
- Chest X-ray confirmed a right lower lobe infiltrate, consistent with pneumonia.
Findings:
- Deep tracheal aspirates and blood cultures identified R. pickettii as the causative agent.
- The VITEK 2 system confirmed the identification, and antibiotic sensitivity testing showed susceptibility to multiple agents, including imipenem/cilastatin.
- The patient received a 14-day course of imipenem/cilastatin, resulting in complete clinical recovery.
Implications:
- This case underscores R. pickettii's potential to cause severe community-acquired lower respiratory tract infections, particularly in immunocompromised or debilitated patients like those with COPD.
- Early identification and appropriate antibiotic therapy are crucial for managing R. pickettii pneumonia and improving patient outcomes.
- Increased awareness among clinicians is necessary to recognize R. pickettii as a significant opportunistic respiratory pathogen.
Related Concept Videos
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
